Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

BMJ Open
06 Jan 2022
https://pubmed.ncbi.nlm.nih.gov/34992118/

Saturday morning Q & A (2017 Conference) (LDN, low dose naltrexone)

Can low-dose naltrexone relieve pain?

The Seattle times
12 Jan 2022
https://www.seattletimes.com/life/wellness/can-low-dose-naltrexone-relieve-pain/

At low doses (1 to 4.5 mg) it is prescribed to ease the pain and inflammation associated with conditions such as fibromyalgia, chronic pain syndrome, multiple sclerosis and Crohn’s disease

Low-dose Naltrexone for atopic dermatitis?

National Eczema Association
11 April 2019
https://nationaleczema.org/naltrexone/

Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial

Trials
15 November 2021
https://pubmed.ncbi.nlm.nih.gov/34781989/

Low-dose naltrexone (LDN)—review of therapeutic utilization

Med Sci (Basel)
21 September 2018
https://pubmed.ncbi.nlm.nih.gov/30248938/